Topic · 7 reports

PBM Rebates

RegulationWatch reporting on pbm rebates matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.

  1. PBM Rebates

    Express Scripts settled the insulin case without paying a cent or admitting a thing.

    The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.

  2. PBM Rebates

    Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.

    Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.

  3. PBM Rebates

    Sixth Circuit keeps Kentucky opioid case against PBMs in federal court

    The Sixth Circuit reversed an order returning Kentucky's opioid lawsuit against Express Scripts and OptumRx to state court. The ruling addressed jurisdiction, without deciding liability.

  4. PBM Rebates

    Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.

    The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.

  5. PBM Rebates

    Louisiana files federal antitrust suit against Express Scripts and Ascent Health Services

    Louisiana Attorney General Liz Murrill has sued Express Scripts, Inc. and its group purchasing affiliate Ascent Health Services LLC in federal court, alleging a conspiracy with Prime Therapeutics to fix pharmacy reimbursement rates. The complaint also alleges that manufacturer rebates were reclassified as fees and that patients were steered to Express Scripts-affiliated pharmacies.

  6. PBM Rebates

    Missouri sues 19 PBMs and insulin makers over alleged pricing scheme

    Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.

  7. PBM Rebates

    CVS Caremark becomes second major PBM to settle FTC insulin rebating case

    The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.